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likely achieved isolation distal to the PV left atrial junction. As
demonstrated in our group 1 results, this approach would have limited
the long-term cure rate. In addition, we have observed that many
recurrences within the first two months’ postprocedure do not
necessarily reflect a “true” failure. The time of assessment of the
procedural success in our series could also have been partially respon-
sible for the difference in the overall cure rate after the first procedure.
We disagree strongly to the conclusion that our patient selection
criteria explain the better outcomes. Indeed, as evidence from our
population (1) shows, it is obvious that we did not exclude any patient
because of a history of AF or the presence of structural heart disease.
In our cohort, nearly 50% of these patients had persistent or
permanent AF, and about 21% had structural heart disease. Our only
selection criteria were the refractoriness to at least two antiarrhythmic
drugs and the presence of symptomatic AF.
Turco et al. also questioned our monitoring protocol postabla-
tion. However, as mentioned in our Methods section, we have
used transtelephonic monitoring in addition to the routine Holter
monitoring. Indeed, 100% of the patients reported in our series
had one month of transtelephonic monitoring, and 96% under-
went an additional month of transtelephonic monitoring during
the six months following the procedure. Analysis of daily trans-
missions in our patients showed markedly different results than
previously reported in other AF studies. As a matter of fact,
asymptomatic episodes of AF were seen only in 2 of the 430
patients who underwent PV isolation at our institution. Con-
versely, 48% of the patients recorded episodes of symptomatic
premature atrial contractions in addition to their daily transmis-
sions. These findings confirm that a highly symptomatic popula-
tion was considered for ablation in our series.
Finally, Turco and colleagues strongly advised placements of
both right and left atrial linear lesions in addition to PV isolation
or as an alternative to PV isolation. However, in our series both
right and left atrial flutters did not appear to be a relevant clinical
problem when all PVs were successfully isolated. In fact, left atrial
flutter was seen only in 3 of 430 patients post-PV isolation.
Similarly, of the 108 patients with preablation documentation of
atrial flutter/AF, only 3 required a right atrial isthmus line after
successful PV isolation (5). In contrast, in our CARTO series (3)
we reported a 20% occurrence of left atrial flutter, which reflected
an inefficient approach in isolating most of the targeted PVs.
Therefore, we do not advocate preemptive placement of linear
lesions, which seems to be important mostly when the PVs are not
effectively isolated. We do realize that ablative strategies for the
treatment of AF are rapidly evolving, and we appreciate the
importance of alternative approaches as long as they are supported
by rigorous testing.
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Statistical Versus Clinical Significance of the
CURE Study in Acute Coronary Syndromes
In a recent issue of JACC, Drs. Khot and Nissen focused on the
statistical versus clinical significance of the Clopidogrel in Unstable
angina to prevent Recurrent Events (CURE) study in acute
coronary syndromes (1). Several of their comments and concerns
are appropriate, but we would like to point out a number of
inaccuracies in their report.
They suggest that the CURE study (2) used a definition of
myocardial infarction (MI) that included patients with only ele-
vated serum troponin levels. In fact, the CURE definition of MI
required at least two of the following: ischemic symptoms; eleva-
tion of markers (creatine kinase-MB fraction or troponin) to at
least twice the upper limit of normal; electrocardiographic changes.
This definition is more strict than the recent European Society of
Cardiology/American College of Cardiology (ESC/ACC) consen-
sus document (3). Further evidence of a reduction in significant
MIs was a 1.2% absolute decline in the rate of subsequent Q-wave
infarctions. All MI events were adjudicated.
With respect to bleeding, it was suggested that the definition of
minor bleeding was revised between the time of ACC presentation
and its publication. In fact, no such change occurred in the
definition. The 15.3% rate of minor bleeding reported by the ACC
was an error that was corrected in the final report.
Regarding the applicability of the CURE trial to practice in the
U.S., the proportion of patients in CURE undergoing cardiac
procedures (catheterization [Cath] 44%; percutaneous coronary
intervention [PCI] 21%; coronary artery bypass graft surgery
[CABG] 16%) is very similar to other recent ACS trials (e.g.,
PURSUIT [4] [Cath 59%; PCI 24%; CABG 14%]). We agree
that clopidogrel should be stopped five days before CABG if at all
possible. With respect to the timing of surgery in U.S. practice,
more recent data from the TACTICS/TIMI-18 study (5) dem-
onstrate that the average time to cardiac surgery in the invasive arm
in the U.S. was 5.5 days. In routine clinical practice outside of a
clinical trial, it is likely that the waiting period is longer. Most
patients in the U.S. who require surgery can therefore potentially
benefit from this medication. In the small percentage of patients
who require early surgery for clinical indications, the increased risk
from bleeding on clopidogrel is only one of the issues that has to
be considered in this high-risk patient group.
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With respect to cost-effectiveness of clopidogrel in acute coro-
nary syndromes, data from the CURE study (6) show that the cost
per event avoided with clopidogrel in the study is comparable to
other cost-effective therapies in cardiovascular disease.
Strategies to prevent major cardiovascular events such as MI,
cardiovascular death, and stroke are clinically important. Preventing
two events per 100 people for nine months of therapy is comparable
to most other treatments in the prevention of cardiovascular events,
including aspirin, beta-blockers, angiotensin-converting enzyme in-
hibitors, and statins in patients following MI (7). Moreover, the
cumulative impact of these various strategies add up to a large benefit.
Therefore, we believe that CURE is not only statistically significant,
but also that the results are clinically relevant and important.
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REPLY
We appreciate the interest by Drs. Joyner and Flather in our
Viewpoint.
We did not intend to imply that troponin elevations alone were
sufficient to meet the end point of myocardial infarction (MI), but
rather that the addition of troponin to creatine kinase-MB fraction
(CK-MB) measurements would increase the number of events
counted as MI within the appropriate clinical context (chest
pain/electrocardiographic changes). Nevertheless, as noted in our
Viewpoint, we acknowledge that clopidogrel reduces nonfatal MI.
The definition of minor bleeding—“other hemorrhages that led
to interruption of the study medication” (1)—is considerably more
selective than that used in other similar clinical trials (2). Requiring
interruption of the study medication to achieve this end point will
dramatically reduce reported minor bleeding (3). Thus, it is
important to know the incidence of minor bleeding with clopi-
dogrel using conventional definitions.
The rate of procedures in Clopidogrel in Unstable angina to
prevent Recurrent Events (CURE), although similar to PURSUIT as
a whole, is markedly less than that for U.S. patients in PURSUIT
(catheterization 83%; percutaneous coronary intervention 35%; coro-
nary artery bypass graft surgery [CABG] 20%) (4). Furthermore, the
rate of revascularization during initial hospitalization is 55% in the
U.S. compared with only 22% in CURE. Thus, CURE reflects a
conservative management strategy not widely used in the U.S.
Citing an average time to surgery of 5.5 days in the U.S. from
TACTICS/TIMI-18, the CURE investigators contend that stop-
ping clopidogrel for five days prior to surgery would not delay the
performance of CABG. This, however, is misleading. For one,
they have chosen to cite the mean time to surgery from random-
ization rather than the median time. The mean time will, by its
nature, be skewed higher by outliers yielding a larger value for the
time to surgery. In contrast, the median time to surgery for all
patients in TACTICS/TIMI-18 was only 3.7 days from random-
ization; it is almost certainly less in the U.S. (5). Furthermore, the
most relevant time frame is the time from catheterization rather
than randomization, as the decision to withhold clopidogrel will
not occur until surgical anatomy is determined by cardiac cathe-
terization. With catheterization being performed a median of one
day after randomization, the CURE investigators are asking
cardiologists and surgeons to routinely delay CABG for an average
of six days after initial presentation. We find it very difficult to
rationalize a routine six-day waiting period in this high-risk
subgroup, who typically have severe left main and/or critical
multivessel coronary artery disease.
Although clopidogrel may be “cost-effective,” this does not
mean that it is without cost. Our simple calculations vividly
illustrate the billions of dollars that would be spent to achieve the
purported benefits of clopidogrel.
Finally, suggesting that clopidogrel is similar to aspirin, beta-
blockers, angiotensin-converting enzyme inhibitors, and statins
greatly overstates its benefit. These four therapies all clearly reduce
mortality; clopidogrel does not. Clopidogrel’s benefit is limited to
nonfatal MI, making it crucially important to account for clinically
significant end points such as major bleeding and strategic con-
cerns regarding early CABG. Accounting for these real risks leads
to the conclusion that routine administration of clopidogrel re-
mains unwarranted, particularly in centers practicing an early
revascularization strategy.
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